NS3 protease inhibitors for treatment of chronic hepatitis C: Efficacy and safety

World Journal of Hepatology

Volumn 6, Issue 5, 2014, Pages 326-339

  Bakulin, Igor ^a   Pasechnikov, Victor ^b   Varlamicheva, Anna ^a   Sannikova, Irina ^b  

^a Central Research Institute of Gastroenterology   (Russian Federation)

^b STAVROPOL STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Adverse event; Antiviral treatment; Hepatitis C virus; Pegylated interferon ; Protease inhibitor; Response guided therapy; Ribavirin

Indexed keywords

EID: 84901455279     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v6.i5.326     Document Type: Article

References (39)

1. Vachon ML, Dieterich DT. The era of direct-acting antivirals has begun: the beginning of the end for HCV? Semin Liver Dis 2011; 31: 399-409 [PMID: 22189979 DOI: 10.1055/ s-0031-1297928].
2. Zignego AL, Craxì A. Extrahepatic manifestations of hepatitis C virus infection. Clin Liver Dis 2008; 12: 611-636, ix [PMID: 18625431 DOI: 10.1016/j.cld.2008.03.012].
3. Chevaliez S, Pawlotsky JM. Diagnosis and management of chronic viral hepatitis: antigens, antibodies and viral genomes. Best Pract Res Clin Gastroenterol 2008; 22: 1031-1048 [PMID: 19187865 DOI: 10.1016/j.bpg.2008.11.004].
4. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5: 453-463 [PMID: 17487147].
5. Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 2007; 132: 1979-1998 [PMID: 17484890].
6. Swan T. Hepatitis C Drug Development Catapults Onward. Pipeline Report. Available from: URL: http://www.pipelinereport.org/2013/hcv.
7. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416 [PMID: 21696307 DOI: 10.1056/NEJMoa1012912].
8. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M, Sankoh AJ, Adda N, Kauffman RS, George S, Wright CI, Poordad F. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-1024 [PMID: 21916639 DOI: 10.1056/NEJMoa1014463].
9. Wilby KJ, Greanya ED, Ford JA, Yoshida EM, Partovi N. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol 2012; 11: 179-185 [PMID: 22345334].
10. Bakulin IG, Fedulenkova LV, Sidorova IO. Safety of Boceprevir and Telaprevir in patients with chronic hepatitis C during triple therapy. Hepatol Forum 2012; 2: 16-20.
11. Roberts SK, Andreone P, Pol S, Younossi Z, Diago M, Lawitz E, Focaccia R, Foster G, Horban A, Lonjon-DomanecoI, DeMas R, Heeswijk R, Picchio G, Witek J, Zeuzem S. Impact of anemia and ribavirin dose reduction on SVR to a telaprevir-based regimen in patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure in the phase III REALIZE study. Hepatology 2011; 54: 1007A-1008.
12. Harrington PR, Zeng W, Naeger LK. Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. Hepatology 2012; 55: 1048-1057 [PMID: 22095516 DOI: 10.1002/hep.24791].
13. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206 [PMID: 21449783 DOI: 10.1056/NEJMoa1010494].
14. Manns M, Reesink H, Berg T, Dusheiko G, Flisiak R, Marcellin P, Moreno C, Lenz O, Meyvisch P, Peeters M, Sekar V, Simmen K, Verloes R. Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial. Antivir Ther 2011; 16: 1021-1033 [PMID: 22024518 DOI: 10.3851/IMP1894].
15. Fried M, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson IM, Marcellin P, Manns MP, Nikitin I, Poordad FF, Sherman M, Zeuzem S, Oliver L, Peeters M, Sekar V, De Smedt G. TMC435 in combination with peginterferon and ribavirin in treatment naiive HCV genotype 1 patients: final analysis of the PILLAR phase IIb study. Hepatology 2011; 54 (Suppl): 1429A.
16. Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, Marcellin P, Manns M, Nikitin I, Poordad F, Sherman M, Zeuzem S, Scott J, Gilles L, Lenz O, Peeters M, Sekar V, De Smedt G, Beumont-Mauviel M. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment- naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013; 58: 1918-1929 [PMID: 23907700 DOI: 10.1002/hep.26641].
17. Foster GR, Fried MW, Hezode C, Hirscheld GM, Nikitin I, Poordad F, Lenz O, Peeters M, Sekar V, De SmedtG.The Aspire Trial: TMC435 in Treatment-experienced Patients with Genotype-1 HCV infection Who Have Failed Previous Pegifn/ rbv Treatment. J Hepatol 2011; 54: S546 [DOI: 10.1016/ S0168-8278(11)61378-0].
18. Lenz O, Fevery B, Vijgen L, Verbeeck J, Peeters M, Beumont- Mauviel M, Zeuzem S, Picchio G. TMC 435 in patients infected with HCV genotype 1 who have failed previous pegylated interferon/ribavirin treatment: virologic analysis of the ASPIRE trial. 47th Annual Meeting of the European Association for the Study of the Liver; 2012 Apr 18-22; Barcelona, Spain: European Association for the Study of the Liver, Abstract 9.
19. Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalskiy VV, Moroz L, Craxì A, Peeters M, Lenz O, Ouwerkerk- Mahadevan S, Kalmeijer R, Beumont-Mauviel M. Simeprevir (TMC435) with Peginterferon/Ribavirin for Chronic HCV Genotype-1 Infection in Treatment-Naive Patients: Results From QUEST-1, a Phase III Trial. 2013 May 18-21; Orlando: Digestive Disease Week, Abstract Sa2072.
20. Poordad F, Manns MP, Marcellin P, Affonso de Araujo ES, Buti M, Horsmans Y, Janczewska E, Villamil F, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, Kalmeijer R, Beumont- Mauviel M. Simeprevir (TMC435) with Peginterferon/Ribavirin for Treatment of Chronic HCV Genotype-1 Infection in Treatment-Naive Patients: Results From QUEST-2, a Phase III Trial. 48th Annual Meeting of the European Association for the Study of the Liver; 2013 May 18-21; Orlando: Digestive Disease Week, Abstract 869a.
21. Scott J, Rosa K, Fu M, Cerri K, Peeters M, Beumont- Mauviel M, Gilles L. Improved SVR with Simeprevir (TMC435) Associated with reduced time with patient-reported fatigue in treatment-naive, HCV-infected patients in the PILLAR phase IIb trial. J Hepatol 2013; 58: S371-372.
22. Sulkowski MS, Asselah T, Lalezari J, Ferenci P, Fainboim H, Leggett B, Bessone F, Mauss S, Heo J, Datsenko Y, Stern JO, Kukolj G, Scherer J, Nehmiz G, Steinmann GG, Böcher WO. Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial. Hepatology 2013; 57: 2143-2154 [PMID: 23359516 DOI: 10.1002/hep.26276].
23. Lawitz E, Forns X, Zeuzem S, Gane E, Bronowicki J-P, Andreone P, Horban A, Brown A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, Kalmeijer R, Beumont-Mauviel M. Simeprevir (TMC435) With Peginterferon/Ribavirin for Treatment of Chronic HCV Genotype 1 Infection in Patients Who Relapsed After Previous Interferon-Based Therapy: Results From PROMISE, a Phase III Trial. 2013 May 18-21. Orlando: Digestive Disease Week, Abstract 869b [DOI: 10.1053/j.gastro.2014.02.051].
24. Sulkowski MS, Bourlière M, Bronowicki JP, Asselah T, Pawlotsky JM, Shafran SD, Pol S, Mauss S, Larrey D, Datsenko Y, Stern JO, Kukolj G, Scherer J, Nehmiz G, Steinmann GG, Böcher WO. Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial. Hepatology 2013; 57: 2155-2163 [PMID: 23504636 DOI: 10.1002/hep.26386].
25. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217 [PMID: 21449784 DOI: 10.1056/NEJMoa1009482].
26. Ferenci P, Asselah T, Foster GR, Zeuzem S, Sarrazin C, Moreno C, Ouzan D, Maevskaya M, Calinas F, Morano LE, Crespo J, Dufour JF, Bourliere M, Agarwal K, Forton D, Schuchmann M, Zehnter E, Nishiguchi S, Omata M, Stern JO, Datzenko Y, Scherer J, Quinson AM. Faldaprevir plus pegylated interferon alfa-2a and Ribavirin in chronic hcv genotype- 1 treatment-naïve Patients: final results from STARTVerso1, a randomised, Double-blind, placebo-controlled phase III trial. J Hepatol 2013; 58: S569.
27. Gottwein JM, Scheel TK, Jensen TB, Ghanem L, Bukh J. Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses. Gastroenterology 2011; 141: 1067-1079 [PMID: 21699793 DOI: 10.1053/j.gastro.2011.06.004].
28. Imhof I, Simmonds P. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191). Hepatology 2011; 53: 1090-1099 [PMID: 21480315 DOI: 10.1002/hep.24172].
29. Gane EJ, Roberts SK, Stedman CA, Angus PW, Ritchie B, Elston R, Ipe D, Morcos PN, Baher L, Najera I, Chu T, Lopatin U, Berrey MM, Bradford W, Laughlin M, Shulman NS, Smith PF. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010; 376: 1467-1475 [PMID: 20951424 DOI: 10.1016/ S0140-6736(10)61384-0].
30. Forestier N, Larrey D, Guyader D, Marcellin P, Rouzier R, Patat A, Smith P, Bradford W, Porter S, Blatt L, Seiwert SD, Zeuzem S. Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study. J Hepatol 2011; 54: 1130-1136 [PMID: 21145848 DOI: 10.1016/j.jhep.2010.11.001].
31. Forestier N, Larrey D, Marcellin P, Guyader D, Patat A, Rouzier R, Smith PF, Qin X, Lim S, Bradford W, Porter S, Seiwert SD, Zeuzem S. Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon a-2a and ribavirin in patients with hepatitis C. J Infect Dis 2011; 204: 601-608 [PMID: 21791662 DOI: 10.1093/infdis/ jir315].
32. Larrey D, Carenco C, Guyader D, Boyer N, Benhamou Y, Pageaux GP, Rouzier R, Marcellin P. Sustained virological response after 14-day treatment with danoprevir and 48-week treatment with pegylated interferon-a2a (40 KD) plus ribavirin. Antivir Ther 2012; 17: 927-932 [PMID: 22611092].
33. Everson G, Cooper C, Hézode C, Shiffman ML, Yoshida E, Beltran-Jaramillo T, Ferenci P, Zeuzem S, Brunda M, Shulman N, Navarro M, Voulgari A, Najera I, Le Pogam S, Yetzer ES. Rapid and sustained achievement of undetectable HCV RNA during treatment with ritonavir-boosted danoprevir/ PEG-IFNa-2A/RBV in HCV genotype 1 or 4 patients: Dauphine week 36 interim analysis. 47th Annual Meeting of the European Association for the Study of Liver Disease; 2012 Apr 18-22; Barcelona, Spain: Digestive Disease Week, Abstract 1177.
34. Marcellin P, Cooper C, Balart L, Larrey D, Box T, Yoshida E, Lawitz E, Buggisch P, Ferenci P, Weltman M, Labriola- Tompkins E, Le Pogam S, Nájera I, Thomas D, Hooper G, Shulman NS, Zhang Y, Navarro MT, Lim CY, Brunda M, Terrault NA, Yetzer ES. Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatmentnaïve patients with hepatitis C virus genotype 1 infection. Gastroenterology 2013; 145: 790-800.e3 [PMID: 23811112 DOI: 10.1053/j.gastro.2013.06.051].
35. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, Reindollar R, Rustgi V, McPhee F, Wind-Rotolo M, Persson A, Zhu K, Dimitrova DI, Eley T, Guo T, Grasela DM, Pasquinelli C. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 216-224 [PMID: 22256805 DOI: 10.1056/NEJMoa1104430].
36. Suzuki Y, Ikeda K, Suzuki F, Toyota J, Karino Y, Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Hu W, Eley T, McPhee F, Hughes E, Kumada H. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 2013; 58: 655-662 [PMID: 23183526 DOI: 10.1016/j.jhep.2012.09.037].
37. Poordad F, Lawitz E, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, Heckaman M, Larsen L, Menon R, Koev G, Tripathi R, Pilot-Matias T, Bernstein B. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013; 368: 45-53 [PMID: 23281975 DOI: 10.1056/NEJMoa1208809].
38. Zeng QL, Zhang JY, Zhang Z, Wang LF, Wang FS. Sofosbuvir and ABT-450: terminator of hepatitis C virus? World J Gastroenterol 2013; 19: 3199-3206 [PMID: 23745021 DOI: 10.3748/wjg.v19.i21.3199].
39. Zeuzem S, Buggisch P, Agarwal K, Marcellin P, Sereni D, Klinker H, Moreno C, Zarski JP, Horsmans Y, Mo H, Arterburn S, Knox S, Oldach D, McHutchison JG, Manns MP, Foster GR. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology 2012; 55: 749-758 [PMID: 22006408 DOI: 10.1002/hep.24744].